Warning: file_get_contents(http://tehnika-news.ru/shells.txt): failed to open stream: Connection refused in /var/sites/p/paperbomb.com/public_html/meds2/1/index.php on line 2
besponsa cd22

besponsa cd22

Перейти к контенту

Главное меню:

Разное
besponsa cd22
About BESPONSA® | BESPONSA®, Besponsa | European Medicines Agency, inotuzumab ozogamicin (Besponsa) - scottishmedicines.org.uk, Inotuzumab ozogamicin - Wikipedia, Besponsa: Uses, Side Effects, Benefits/Risks | Drugs.com, Besponsa (Inotuzumab Ozogamicin) | Lymphoma News Today, BESPONSA® (inotuzumab ozogamicin) Fact Sheet, US regulators wave through Pfizer’s leukaemia drug , BESPONSA 1 mg powder for concentrate for solution for .
BESPONSA is associated with a risk of liver problems and increased risk of death after stem cell transplant. BESPONSA can cause liver problems that can be severe, life-threatening, or fatal, including a condition called veno-occlusive disease (VOD). This condition can occur during treatment with BESPONSA or following subsequent treatment with a stem cell transplant. This condition was more common in patients who had elevated liver tests or who received dual alkylating agents in preparation for their stem cell transplant. Patients may be at a higher risk of VOD if they:. BESPONSA is a type of medicine called an antibody-drug conjugate. BESPONSA is designed to find and attach to a specific protein, called CD22, found on leukemia cells; Once BESPONSA attaches to the CD22 protein, it enters the cell to deliver the drug, causing cell death. Besponsa is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI)..
inotuzumab ozogamicin (BESPONSA®) is accepted for restricted use within NHSScotland. Indication under review: as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL).. History. In 2017 inotuzumab ozogamicin was approved by the European Commission and the FDA for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in 2017 under the trade name Besponsa (Pfizer/Wyeth).. Besponsa is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).. Besponsa (inotuzumab ozogamicin, In around 90 percent of ALL cases, the cancerous cells express a protein called CD22. Besponsa is an antibody-drug conjugate (ADC). The antibody, or protein designed to bind to a specific target, interacts with CD22 found on the surface of ALL cancer cells. This interaction causes the cell to absorb Besponsa. The drug, calicheamicin, which is conjugated to . BESPONSA® (inotuzumab ozogamicin) Fact Sheet BESPONSA® (inotuzumab ozogamicin) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody (mAb) targeting CD22, a cell surface antigen expressed on cancer cells in almost all B-cell. The US Food and Drug Administration has approved Pfizer’s Besponsa, the first and only CD22-directed antibody-drug conjugate indicated to treat relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL)..
 
Copyright 2019. All rights reserved.
Назад к содержимому | Назад к главному меню